Middle east respiratory syndrome

New England Journal of Medicine

Volumn 376, Issue 6, 2017, Pages 584-594

  Arabi, Yaseen M ^a   Balkhy, Hanan H ^a   Hayden, Frederick G ^d   Bouchama, Abderrezak ^a   Luke, Thomas ^e   Baillie, J Kenneth ^f   Al omari, Awad ^b,c   Hajeer, Ali H ^a   Senga, Mikiko ⁱ   Denison, Mark R ^j   Nguyen Van Tam, Jonathan S ^g   Shindo, Nahoko ⁱ   Bermingham, Alison ^h   Chappell, James D ^k   Van Kerkhove, Maria D ^l   Fowler, Robert A ^i,m  

^a KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^b Manama   (Saudi Arabia)

^c ALFAISAL UNIVERSITY   (Saudi Arabia)

^d UNIVERSITY OF VIRGINIA   (United States)

^e NAVAL MEDICAL RESEARCH CENTER   (United States)

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

^g UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^h PUBLIC HEALTH ENGLAND   (United Kingdom)

ⁱ WORLD HEALTH ORGANIZATION   (Switzerland)

^j VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k INSTITUT PASTEUR   (France)

^l UNIVERSITY OF TORONTO   (Canada)

^m SUNNYBROOK RESEARCH INSTITUTE   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 5; DIPEPTIDYL PEPTIDASE IV; GLUCOCORTICOID; INTERFERON; INTERFERON BETA SERINE; LOPINAVIR PLUS RITONAVIR; MEMBRANE PROTEIN; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA; VIRUS VACCINE;

ANTIBODY DETECTION; ANTIVIRAL THERAPY; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL FEATURE; COMMUNITY ACQUIRED INFECTION; CORTICOSTEROID THERAPY; DROMEDARY; ENVIRONMENTAL EXPOSURE; EPIDEMIC; HOSPITAL INFECTION; INFECTION PREVENTION; INFECTION RISK; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOLECULAR DIAGNOSTICS; MORTALITY; PATHOGENESIS; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY EPITHELIUM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAUDI ARABIA; SEROEPIDEMIOLOGY; TRAVEL; VIRUS CELL INTERACTION; VIRUS CULTURE; VIRUS ENTRY; VIRUS IMMUNITY; VIRUS MORPHOLOGY; VIRUS REPLICATION; VIRUS TRANSMISSION; VIRUS VIRULENCE; ZOONOSIS; ANIMAL; CORONAVIRUS INFECTIONS; DISEASE MODEL; DISEASE TRANSMISSION; HUMAN; MIDDLE EAST; PHYSIOLOGY; RISK FACTOR; TRANSMISSION;

ANIMALS; CORONAVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; DISEASE TRANSMISSION, INFECTIOUS; HUMANS; MIDDLE EAST; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; RISK FACTORS;

EID: 85012850972     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMsr1408795     Document Type: Article

References (74)

1. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367: 1814-20.
2. World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV) (http://www.who.int/emergencies/mers-cov/en/).
3. Faure E, Poissy J, Goffard A, et al. Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside? PLoS One 2014; 9(2): E88716.
4. Falzarano D, de Wit E, Rasmussen AL, et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoVinfected rhesus macaques. Nat Med 2013; 19: 1313-7.
5. Azhar EI, El-Kafrawy SA, Farraj SA, et al. Evidence for camelto- human transmission of MERS coronavirus. N Engl J Med 2014; 370: 2499-505.
6. Alraddadi BM, Watson JT, Almarashi A, et al. Risk factors for primary Middle East respiratory syndrome coronavirus illness in humans, Saudi Arabia, 2014. Emerg Infect Dis 2016; 22: 49-55.
7. Muller MA, Meyer B, Corman VM, et al. Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: A nationwide, cross-sectional, serological study. Lancet Infect Dis 2015; 15: 559-64.
8. Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabeeah AA, Stephens GM. Family cluster of Middle East respiratory syndrome coronavirus infections. N Engl J Med 2013; 368: 2487-94.
9. Drosten C, Meyer B, Muller MA, et al. Transmission of MERS-coronavirus in household contacts. N Engl J Med 2014; 371: 828-35.
10. Arwady MA, Alraddadi B, Basler C, et al. Middle East respiratory syndrome coronavirus transmission in extended family, Saudi Arabia, 2014. Emerg Infect Dis 2016; 22: 1395-402.
11. Kraaij-Dirkzwager M, Timen A, Dirksen K, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) infections in two returning travellers in the Netherlands, May 2014. Euro Surveill 2014; 19(21): 20817.
12. Oboho IK, Tomczyk SM, Al-Asmari AM, et al. 2014 MERSCoV outbreak in Jeddah -A link to health care facilities. N Engl J Med 2015; 372: 846-54.
13. Al-Gethamy M, Corman VM, Hussain R, Al-Tawfiq JA, Drosten C, Memish ZA. A case of long-Term excretion and subclinical infection with Middle East respiratory syndrome coronavirus in a healthcare worker. Clin Infect Dis 2015; 60: 973-4.
14. Ki M. 2015 MERS outbreak in Korea: hospital-To-hospital transmission. Epidemiol Health 2015; 37: E2015033.
15. Al-Abdallat MM, Payne DC, Alqasrawi S, et al. Hospitalassociated outbreak of Middle East respiratory syndrome coronavirus: A serologic, epidemiologic, and clinical description. Clin Infect Dis 2014; 59: 1225-33.
16. Balkhy HH, Alenazi TH, Alshamrani MM, et al. Description of a hospital outbreak of Middle East respiratory syndrome in a large tertiary care hospital in Saudi Arabia. Infect Control Hosp Epidemiol 2016; 37: 1147-55.
17. Korea Centers for Disease Control and Prevention. Corrigendum to "Middle East Respiratory Syndrome Coronavirus Outbreak in the Republic of Korea, 2015" [Volume 6, Issue 4, August 2015, 269-278]. Osong Public Health Res Perspect 2016; 7: 138.
18. World Health Organization. Infection prevention and control during health care for probable or confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection. June 4, 2015 (http://apps.who.int/iris/bitstream/10665/174652/1/WHO-MERS-IPC-15.1-eng.pdf?ua=1).
19. Bin SY, Heo JY, Song MS, et al. Environmental contamination and viral shedding in MERS patients during MERS-CoV outbreak in South Korea. Clin Infect Dis 2016; 62: 755-60.
20. Kim SH, Chang SY, Sung M, et al. Extensive viable Middle East respiratory syndrome (MERS) coronavirus contamination in air and surrounding environment in MERS isolation wards. Clin Infect Dis 2016; 63: 363-9.
21. Schneider E, Chommanard C, Rudd J, Whitaker B, Lowe L, Gerber SI. Evaluation of patients under investigation for MERSCoV infection, United States, January 2013-October 2014. Emerg Infect Dis 2015; 21: 1220-3.
22. Al-Tawfiq JA, Omrani AS, Memish ZA. Middle East respiratory syndrome coronavirus: current situation and travel-Associated concerns. Front Med 2016; 10: 111-9.
23. Camel is absent for the second year from the Hajj scene. Alriyadh. September 5, 2016 (http://www.alriyadh.com/1531133).
24. Memish ZA, Al-Tawfiq JA, Assiri A, et al. Middle East respiratory syndrome coronavirus disease in children. Pediatr Infect Dis J 2014; 33: 904-6.
25. de Groot RJ, Baker SC, Baric RS, et al. Middle East respiratory syndrome coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group. J Virol 2013; 87: 7790-2.
26. van Boheemen S, de Graaf M, Lauber C, et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio 2012; 3(6): 00473-12.
27. Smith EC, Blanc H, Surdel MC, Vignuzzi M, Denison MR. Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: Evidence for proofreading and potential therapeutics. PLoS Pathog 2013; 9(8): E1003565.
28. Chan CM, Chu H, Wang Y, et al. Carcinoembryonic antigenrelated cell adhesion molecule 5 is an important surface attachment factor that facilitates entry of the Middle East respiratory syndrome coronavirus. J Virol 2016; 90: 9114-27.
29. Gierer S, Bertram S, Kaup F, et al. The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. J Virol 2013; 87: 5502-11.
30. Millet JK, Whittaker GR. Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Proc Natl Acad Sci U S A 2014; 111: 15214-9.
31. Muth D, Corman VM, Meyer B, et al. Infectious Middle East respiratory syndrome coronavirus excretion and serotype variability based on live virus isolates from patients in Saudi Arabia. J Clin Microbiol 2015; 53: 2951-5.
32. Jiang L, Wang N, Zuo T, et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci Transl Med 2014; 6: 234ra59.
33. Tang XC, Agnihothram SS, Jiao Y, et al. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc Natl Acad Sci U S A 2014; 111: E2018-E2026.
34. The FANTOM Consortium and the RIKEN PMI and CLST (DGT). A promoter-level mammalian expression atlas. Nature 2014; 507: 462-70.
35. Chan JF, Chan KH, Choi GK, et al. Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation. J Infect Dis 2013; 207: 1743-52.
36. Hocke AC, Becher A, Knepper J, et al. Emerging human middle East respiratory syndrome coronavirus causes widespread infection and alveolar damage in human lungs. Am J Respir Crit Care Med 2013; 188: 882-6.
37. de Wit E, Rasmussen AL, Falzarano D, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc Natl Acad Sci U S A 2013; 110: 16598-603.
38. Falzarano D, de Wit E, Feldmann F, et al. Infection with MERS-CoV causes lethal pneumonia in the common marmoset. PLoS Pathog 2014; 10(8): E1004250.
39. Corman VM, Albarrak AM, Omrani AS, et al. Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection. Clin Infect Dis 2016; 62: 477-83.
40. Memish ZA, Assiri AM, Al-Tawfiq JA. Middle East respiratory syndrome coronavirus (MERS-CoV) viral shedding in the respiratory tract: An observational analysis with infection control implications. Int J Infect Dis 2014; 29: 307-8.
41. Kim SY, Park SJ, Cho SY, et al. Viral RNA in blood as indicator of severe outcome in Middle East respiratory syndrome coronavirus infection. Emerg Infect Dis 2016; 22: 1813-6.
42. Shalhoub S, Farahat F, Al-Jiffri A, et al. IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: A retrospective study. J Antimicrob Chemother 2015; 70: 2129-32.
43. van Doremalen N, Miazgowicz KL, Milne-Price S, et al. Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4. J Virol 2014; 88: 9220-32.
44. Zhao J, Li K, Wohlford-Lenane C, et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci U S A 2014; 111: 4970-5.
45. Agrawal AS, Garron T, Tao X, et al. Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. J Virol 2015; 89: 3659-70.
46. Munster VJ, de Wit E, Feldmann H. Pneumonia from human coronavirus in a macaque model. N Engl J Med 2013; 368: 1560-2.
47. Chan JF, Yao Y, Yeung ML, et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis 2015; 212: 1904-13.
48. Johnson RF, Via LE, Kumar MR, et al. Intratracheal exposure of common marmosets to MERS-CoV Jordan-n3/2012 or MERSCoV EMC/2012 isolates does not result in lethal disease. Virology 2015; 485: 422-30.
49. Ng DL, Al Hosani F, Keating MK, et al. Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of Middle East respiratory syndrome coronavirus infection in the United Arab Emirates, April 2014. Am J Pathol 2016; 186: 652-8.
50. Mielech AM, Kilianski A, Baez-Santos YM, Mesecar AD, Baker SC. MERS-CoV papain-like protease has deISGylating and deubiquitinating activities. Virology 2014; 450-451: 64-70.
51. Lokugamage KG, Narayanan K, Nakagawa K, et al. Middle East respiratory syndrome coronavirus nsp1 inhibits host gene expression by selectively targeting nuclear-Transcribed mRNAs but spares mRNAs of cytoplasmic origin. J Virol 2015; 89: 10970- 81.
52. Yang Y, Zhang L, Geng H, et al. The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists. Protein Cell 2013; 4: 951-61.
53. Liu DX, Fung TS, Chong KK, Shukla A, Hilgenfeld R. Accessory proteins of SARS-CoV and other coronaviruses. Antiviral Res 2014; 109: 97-109.
54. Josset L, Menachery VD, Gralinski LE, et al. Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. MBio 2013; 4(3): E00165-e13.
55. Park WB, Perera RA, Choe PG, et al. Kinetics of serologic responses to MERS coronavirus infection in humans, South Korea. Emerg Infect Dis 2015; 21: 2186-9.
56. Min CK, Cheon S, Ha NY, et al. Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. Sci Rep 2016; 6: 25359.
57. Arabi YM, Hajeer AH, Luke T, et al. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerg Infect Dis 2016; 22: 1554-61.
58. Arabi YM, Arifi AA, Balkhy HH, et al. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med 2014; 160: 389-97.
59. Payne DC, Iblan I, Alqasrawi S, et al. Stillbirth during infection with Middle East respiratory syndrome coronavirus. J Infect Dis 2014; 209: 1870-2.
60. Arabi YM, Harthi A, Hussein J, et al. Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV). Infection 2015; 43: 495-501.
61. World Health Organization. Surveillance for human infection with Middle East respiratory syndrome coronavirus (MERSCoV): interim guidance. June 30, 2015 (http://www.who.int/csr/disease/coronavirus-infections/surveillance-human-infection-mers/en/).
62. Memish ZA, Al-Tawfiq JA, Makhdoom HQ, et al. Respiratory tract samples, viral load, and genome fraction yield in patients with Middle East respiratory syndrome. J Infect Dis 2014; 210: 1590-4.
63. WHO Mers-Cov Research Group. State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans. PLoS Curr 2013; 5.
64. Corman VM, Muller MA, Costabel U, et al. Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. Euro Surveill 2012; 17(49): 20334.
65. Corman VM, Eckerle I, Bleicker T, et al. Detection of a novel human coronavirus by real-Time reverse-Transcription polymerase chain reaction. Euro Surveill 2012; 17: 20285.
66. Drosten C, Muth D, Corman VM, et al. An observational, laboratory-based study of outbreaks of Middle East respiratory syndrome coronavirus in Jeddah and Riyadh, Kingdom of Saudi Arabia, 2014. Clin Infect Dis 2015; 60: 369-77.
67. Omrani AS, Saad MM, Baig K, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: A retrospective cohort study. Lancet Infect Dis 2014; 14: 1090-5.
68. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory metaanalysis. J Infect Dis 2015; 211: 80-90.
69. Auyeung TW, Lee JS, Lai WK, et al. The use of corticosteroid as treatment in SARS was associated with adverse outcomes: A retrospective cohort study. J Infect 2005; 51: 98-102.
70. Chan JF, Chan KH, Kao RY, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect 2013; 67: 606-16.
71. Zumla A, Azhar EI, Arabi Y, et al. Host-directed therapies for improving poor treatment outcomes associated with the middle east respiratory syndrome coronavirus infections. Int J Infect Dis 2015; 40: 71-4.
72. Agrawal AS, Tao X, Algaissi A, et al. Immunization with inactivated Middle East respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccin Immunother 2016; 12: 2351-6.
73. Dunning JW, Merson L, Rohde GG, et al. Open source clinical science for emerging infections. Lancet Infect Dis 2014; 14: 8-9.
74. Van Kerkhove MD, Broberg E, Engelhardt OG, Wood J, Nicoll A. The Consortium for the Standardization of Influenza Seroepidemiology (CONSISE): A global partnership to standardize influenza seroepidemiology and develop influenza investigation protocols to inform public health policy. Influenza Other Respir Viruses 2013; 7: 231-4.